FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD) [Yahoo! Finance]
Revolution Medicines, Inc. (RVMD)
Company Research
Source: Yahoo! Finance
ductal adenocarcinoma and, in June 2025, received US FDA Breakthrough Therapy Designation for previously treated patients with KRAS G12-mutant disease. This regulatory milestone highlights Revolution Medicines' emerging role in precision oncology, where targeting RAS-pathway mutations is becoming increasingly important for difficult-to-treat cancers like pancreatic cancer. We'll now examine how the Breakthrough Therapy Designation for daraxonrasib shapes Revolution Medicines' investment narrative and future growth expectations. The latest GPUs need a type of rare earth metal called Terbium and there are only 37 companies in the world exploring or producing it . Find the list for free. To own Revolution Medicines, you have to believe that its RAS-focused pipeline can translate scientific precision into real commercial therapies before the cash burn and dilution risks bite too hard. The recent Breakthrough Therapy Designation for daraxonrasib in KRAS G12-mutant pancreatic cancer
Show less
Read more
Impact Snapshot
Event Time:
RVMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVMD alerts
High impacting Revolution Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
RVMD
News
- Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- Healthcare stocks are red-hot. Here are 3 picks from a fund manager up 41% this year. [Business Insider]Business Insider
- Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.MarketBeat
- Revolution Medicines (NASDAQ:RVMD) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $75.00 price target on the stock.MarketBeat
- Hot Picks: Cancer-focused biotech firms gain attention as key clinical results near [BNN Bloomberg (Canada)]BNN Bloomberg
RVMD
Earnings
- 11/5/25 - Miss
RVMD
Sec Filings
- 12/12/25 - Form 144
- 12/12/25 - Form 144
- 12/12/25 - Form 144
- RVMD's page on the SEC website